Crossmark

A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma

Crossref DOI link: https://doi.org/10.1038/s41392-025-02530-2

Published Online: 2025-12-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xue, Ran

Wei, Miaoyan

Yuan, Jiajia

Li, Zhihua

Zhou, Yuhong

Xue, Zeyun

Wu, Yiwen

Han, Hongxia

Zhou, Jun

Yu, Xianjun https://orcid.org/0000-0002-6697-7143
Shen, Lin https://orcid.org/0000-0002-8798-4756
Funding

Funding for this research was provided by:

This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
License Information

Text and Data Mining valid from 2025-12-20

Version of Record valid from 2025-12-20
More Information

Article History

Received: 21 January 2025

Revised: 2 September 2025

Accepted: 1 December 2025

First Online: 20 December 2025

Competing interests

: Zeyun Xue, Yiwen Wu, and Hongxia Han report being employed by Jiangsu Hengrui Pharmaceuticals. All other authors declare no competing interests.

Document is current

Any future updates will be listed below